MDM2 protein expression is a negative prognostic marker in breast carcinoma.
about
Novel RING E3 ubiquitin ligases in breast cancerResistance and gain-of-resistance phenotypes in cancers harboring wild-type p53Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations.Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma.Fulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugsMDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group.A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferationDifferential expression of arrestins is a predictor of breast cancer progression and survival.The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast cancer.Impaired p53 function leads to centrosome amplification, acquired ERalpha phenotypic heterogeneity and distant metastases in breast cancer MCF-7 xenografts.Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer.Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2/REST pathway in human breast cancer.Mouse double minute 2 (MDM2) upregulates Snail expression and induces epithelial-to-mesenchymal transition in breast cancer cells in vitro and in vivo.Gossypol has anti-cancer effects by dual-targeting MDM2 and VEGF in human breast cancer.Role of E3 ubiquitin ligases in lung cancer.Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway.Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.MDM2 Contributes to High Glucose-Induced Glomerular Mesangial Cell Proliferation and Extracellular Matrix Accumulation via Notch1Inhibitory effect of naringenin via IL-13 level regulation on thymic stromal lymphopoietin-induced inflammatory reactions.Loss of Diacylglycerol Kinase-Ζ Inhibits Cell Proliferation and Survival in Human Gliomas.ERβ alters the chemosensitivity of luminal breast cancer cells by regulating p53 function.Overview of MDM2 and B-RAF Expression in Gastric Lesions
P2860
Q24300517-76572ED2-02BB-487E-96A9-9F5EB4542511Q27006998-D4005F3C-410A-4107-9283-F61F3857BF21Q33410398-40572D7E-15F8-4F65-BF5B-D3F311FC3D50Q33601430-5E97C0DA-38FC-4E42-A83D-6DBE201068EFQ33880170-4B5307AE-95CE-4F6A-B2DD-D30D9419CC72Q34043467-3556346E-2C97-4944-986B-CE8D66F7A4C6Q35029505-58928E44-791B-4388-A909-D9970C7CA0EEQ35166797-7A4E57FD-5896-49B1-9B86-9E6B84897B88Q36049982-9992780F-A903-4B0D-A96F-3E26AFF898E3Q36852947-C4604234-C37D-4AF7-9DBF-EC5E597787E4Q37093018-D9C8A4DC-057F-4F61-8C83-7DF8B0BD0040Q37269178-A29FDDF8-FCD9-4B80-9FF0-21BFE7F45DB8Q37392937-1F85E63A-1E4E-4E97-A75F-BAF63916B53CQ37690082-08BE9F2E-2583-4BDB-8E49-D23552C57027Q38128316-9DACDB2F-59CA-47D4-BD3D-679609EC24C1Q38725313-1F79D852-65C1-4E77-B13C-17716072A04EQ39116877-36494400-B127-44EE-91E6-C25BE87AB0E4Q41605810-C90C31BA-1102-44C3-A7D4-02FFEF36F4E1Q47548202-30A0DCDE-9EC8-45FE-8EBE-FD7B8A53B149Q50926299-C5C7A780-E085-408A-8589-BCDE0D6AC348Q55421291-30B8E6B2-84B8-4018-B7D8-488675A37BADQ59129460-380E7ACA-E759-4E54-836C-3D2114523C9D
P2860
MDM2 protein expression is a negative prognostic marker in breast carcinoma.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
MDM2 protein expression is a negative prognostic marker in breast carcinoma.
@en
type
label
MDM2 protein expression is a negative prognostic marker in breast carcinoma.
@en
prefLabel
MDM2 protein expression is a negative prognostic marker in breast carcinoma.
@en
P2093
P2860
P1433
P1476
MDM2 protein expression is a negative prognostic marker in breast carcinoma
@en
P2093
Alessandro De Luca
C Blake Gilks
Chris D Bajdik
David G Huntsman
Dmitry A Turbin
Erika Yorida
Karen A Gelmon
Torsten O Nielsen
P2860
P2888
P356
10.1038/MODPATHOL.3800484
P577
2006-01-01T00:00:00Z
P5875
P6179
1046301350